Journal Article

DKFZ-2025-01535

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma.

Schadendorf, D.DKFZ*

2025
Taylor & Francis London

Abstract: This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.

Keyword(s): 7-year update ; BRAF V600 ; COLUMBUS ; Lead author commentary ; binimetinib ; encorafenib ; melanoma ; vemurafenib

Note: 2025 Sep;21(21):2701-2703 / MULTIMEDIA ARTICLE

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---